257 related articles for article (PubMed ID: 36874378)
1. Therapy-related core binding factor acute myeloid leukemia.
George B; Yohannan B; Mohlere V; Gonzalez A
Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
[TBL] [Abstract][Full Text] [Related]
2. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
[TBL] [Abstract][Full Text] [Related]
5. Primary peritoneal myeloid sarcoma in association with
Kuhlman JJ; Abdel Rahman ZH; Jiang L; Menke DM; Foran JM; Murthy HS
Leuk Res Rep; 2021; 15():100238. PubMed ID: 33816105
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.
Shurtleff SA; Meyers S; Hiebert SW; Raimondi SC; Head DR; Willman CL; Wolman S; Slovak ML; Carroll AJ; Behm F
Blood; 1995 Jun; 85(12):3695-703. PubMed ID: 7780153
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
9. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Marcucci G; Geyer S; Laumann K; Zhao W; Bucci D; Uy GL; Blum W; Eisfeld AK; Pardee TS; Wang ES; Stock W; Kolitz JE; Kohlschmidt J; Mrózek K; Bloomfield CD; Stone RM; Larson RA
Blood Adv; 2020 Feb; 4(4):696-705. PubMed ID: 32092139
[TBL] [Abstract][Full Text] [Related]
10. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
Marcucci G; Caligiuri MA; Bloomfield CD
Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
13. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract][Full Text] [Related]
14. Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).
Kawashima N; Shimada A; Taketani T; Hayashi Y; Yoshida N; Matsumoto K; Takahashi Y; Kojima S; Kato K
Int J Hematol; 2012 May; 95(5):577-80. PubMed ID: 22403058
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Gustafson SA; Lin P; Chen SS; Chen L; Abruzzo LV; Luthra R; Medeiros LJ; Wang SA
Am J Clin Pathol; 2009 May; 131(5):647-55. PubMed ID: 19369623
[TBL] [Abstract][Full Text] [Related]
16. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
17. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
18. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
20. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
